Abstract
The present study was motivated to evaluate the anticancer potential of platinum(II)-pyrazinecarboxamide-bipyridine complex (PCABpy-Pt) against Ehrlich ascites carcinoma (EAC) cells induced in mice. 150 mice were divided equally to five groups: control healthy mice, EAC bearing mice (mice were ip. inoculated with 2x106 EAC cells/mouse), vehicle group (mice were ip. injected with 0.2 ml of DMSO: H2O, 4: 1 v/v, 3 times/week, for 2 weeks), platinum complex group (mice were ip. injected with 80 mg/Kg freshly dissolved PCABpy-Pt complex in a vehicle, 3 times/week, for 2 weeks) and treated EAC-inoculated mice group (mice were inoculated with EAC followed by treatment after 24 h with the same dose of Pt drug as in Pt complex group). Results indicated that treatment with the drug prevents the accumulation of ascetic fluid and consequently decreased the cell viability with increasing non-viable cell count, which in turn resulted in 58 % increased life span of tumor bearing mice. Hematological profile reverted to normal values by treatment. All the biochemical parameters of EAC bearing mice including liver, kidney, lipid profile and cardiac enzymes were improved by treatment reaching almost values comparable to those in healthy animals. The complex had significantly enhanced the antioxidant activity of the treated mice. Significant improvement in histopathological examinations of vital organs including heart, liver, kidney, lung and spleen were noted by treatment. No significant variations were detected in all biochemical parameters by injecting the drug to healthy animals. The study concluded that the complex proved to have a potential role as an anticancer agent probably through its antioxidant properties.